Transforming Growth Factor-β Protects against Inflammation-Related Atherosclerosis in South African CKD Patients

Table 5

TGF-β1 T-869C and G-915C SNPs distribution and frequency in study participants.

SNPs /Producer	CKD patients (n=79)	Controls (n=32)	P-value
T/T G/G (high)	16 (20.3%)	7 (21.9%)	1.00
T/C G/G (high)	41 (51.9%)	17 (53.1%)	1.00
T/C G/C (intermediate)	6 (7.6%)	5 (15.6%)	0.29
C/C G/G (intermediate)	9 (11.4%)	1 (3.1%)	0.28
T/T G/C (intermediate)	1 (1.3%)	0 (0%)	1.00
C/C G/C (low)	5 (6.3%)	2 (6.3%)	1.00
T/C C/C (low)	1 (1.3%)	0 (0%)	1.00

TGF-β1, transforming growth factor β1; T-869C, rs1800470; G-915C, rs1800471. P-values were calculated using Chi-square and Fisher’s exact test where applicable. From the analysis of the SNPs, there was no difference between CKD patients and the controls (p>0.05).